JPWO2021132311A1 - - Google Patents

Info

Publication number
JPWO2021132311A1
JPWO2021132311A1 JP2021567520A JP2021567520A JPWO2021132311A1 JP WO2021132311 A1 JPWO2021132311 A1 JP WO2021132311A1 JP 2021567520 A JP2021567520 A JP 2021567520A JP 2021567520 A JP2021567520 A JP 2021567520A JP WO2021132311 A1 JPWO2021132311 A1 JP WO2021132311A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021567520A
Other languages
Japanese (ja)
Other versions
JPWO2021132311A5 (https=
JP7662534B2 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2021132311A1 publication Critical patent/JPWO2021132311A1/ja
Publication of JPWO2021132311A5 publication Critical patent/JPWO2021132311A5/ja
Application granted granted Critical
Publication of JP7662534B2 publication Critical patent/JP7662534B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2021567520A 2019-12-24 2020-12-23 脂肪族酸アミド誘導体 Active JP7662534B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019232927 2019-12-24
JP2019232927 2019-12-24
PCT/JP2020/048117 WO2021132311A1 (ja) 2019-12-24 2020-12-23 脂肪族酸アミド誘導体

Publications (3)

Publication Number Publication Date
JPWO2021132311A1 true JPWO2021132311A1 (https=) 2021-07-01
JPWO2021132311A5 JPWO2021132311A5 (https=) 2023-12-12
JP7662534B2 JP7662534B2 (ja) 2025-04-15

Family

ID=76574184

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021567520A Active JP7662534B2 (ja) 2019-12-24 2020-12-23 脂肪族酸アミド誘導体

Country Status (14)

Country Link
US (3) US12503463B2 (https=)
EP (1) EP4082616B1 (https=)
JP (1) JP7662534B2 (https=)
KR (1) KR20220120625A (https=)
CN (1) CN114981264B (https=)
AU (1) AU2020413284A1 (https=)
BR (1) BR112022011844A2 (https=)
CA (1) CA3161806A1 (https=)
ES (1) ES3040677T3 (https=)
HU (1) HUE072877T2 (https=)
MX (1) MX2022007947A (https=)
PL (1) PL4082616T3 (https=)
PT (1) PT4082616T (https=)
WO (1) WO2021132311A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220120625A (ko) * 2019-12-24 2022-08-30 스미토모 파마 가부시키가이샤 지방족 산 아미드 유도체
JP7655885B2 (ja) * 2021-06-30 2025-04-02 住友ファーマ株式会社 脂肪族酸アミド誘導体を含有する医薬組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01168677A (ja) * 1987-11-30 1989-07-04 Bristol Myers Co 向精神性非環式アミド誘導体
JPH093060A (ja) * 1995-03-17 1997-01-07 Hoechst Marion Roussel Inc 置換されたベンゾチエニルピペラジン、医薬としてのその使用およびその製法
JP2006508101A (ja) * 2002-11-08 2006-03-09 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー フェニルアルキルおよびピリジルアルキルピペラジン誘導体
JP2008539268A (ja) * 2005-04-26 2008-11-13 ハイプニオン・インコーポレイテッド ベンズイソオキサゾールピペラジン化合物およびその使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880121A (en) * 1996-01-05 1999-03-09 Hoechst Marion Roussel Inc. 4,5-dihydronaphth (1,2-c) isoxazoles and derivatives thereof
JP4497815B2 (ja) 2001-02-16 2010-07-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド 新規な複素環式アミド誘導体およびドーパミンd3受容体リガンドとしてのその使用
FR2827287B1 (fr) * 2001-07-13 2003-10-31 Servier Lab Nouveaux derives de benzene sulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PL392436A1 (pl) 2010-09-17 2012-03-26 Adamed Spółka Z Ograniczoną Odpowiedzialnością Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego
WO2014079155A1 (zh) * 2012-11-26 2014-05-30 辽宁贝雷生物制药有限公司 苯并五元氮杂环基哌嗪或哌啶衍生物的用途
KR20220120625A (ko) * 2019-12-24 2022-08-30 스미토모 파마 가부시키가이샤 지방족 산 아미드 유도체

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01168677A (ja) * 1987-11-30 1989-07-04 Bristol Myers Co 向精神性非環式アミド誘導体
JPH093060A (ja) * 1995-03-17 1997-01-07 Hoechst Marion Roussel Inc 置換されたベンゾチエニルピペラジン、医薬としてのその使用およびその製法
JP2006508101A (ja) * 2002-11-08 2006-03-09 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー フェニルアルキルおよびピリジルアルキルピペラジン誘導体
JP2008539268A (ja) * 2005-04-26 2008-11-13 ハイプニオン・インコーポレイテッド ベンズイソオキサゾールピペラジン化合物およびその使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NORMAN, MARK H. ET AL.: "Synthesis and Evaluation of Heterocyclic Carboxamides as Potential Antipsychotic Agents", J. MED. CHEM., vol. 39, JPN6021004911, 1996, pages 4692 - 4703, XP055837896, ISSN: 0005452257, DOI: 10.1021/jm9603375 *
REGISTRY(STN)[ONLINE], JPN7024004569, 4 June 2019 (2019-06-04), pages 1, ISSN: 0005452258 *

Also Published As

Publication number Publication date
US12503463B2 (en) 2025-12-23
TW202136235A (zh) 2021-10-01
KR20220120625A (ko) 2022-08-30
CA3161806A1 (en) 2021-07-01
EP4082616A1 (en) 2022-11-02
US20220073506A1 (en) 2022-03-10
US20260078115A1 (en) 2026-03-19
BR112022011844A2 (pt) 2022-08-30
WO2021132311A1 (ja) 2021-07-01
EP4082616B1 (en) 2025-09-03
US11339151B2 (en) 2022-05-24
JP7662534B2 (ja) 2025-04-15
CN114981264A (zh) 2022-08-30
PL4082616T3 (pl) 2025-12-15
MX2022007947A (es) 2022-07-27
EP4082616A4 (en) 2024-01-03
AU2020413284A1 (en) 2022-08-18
US20220213079A1 (en) 2022-07-07
PT4082616T (pt) 2025-12-02
HUE072877T2 (hu) 2025-12-28
CN114981264B (zh) 2024-07-26
ES3040677T3 (en) 2025-11-04

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
BR112021017728A2 (https=)
AU2020104490A5 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016142A2 (https=)
BR112019016138A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)
BR112021017173A2 (https=)
BR112021018250A2 (https=)
BR112021018584A2 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241223

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250325

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250403

R150 Certificate of patent or registration of utility model

Ref document number: 7662534

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150